An observational study in Breast Cancer, sponsored by Federal University of São Paulo. Enrolling by invitation at 13 sites in 8 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Federal University of São Paulo · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.
Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 3rd largest by planned enrollment of the 40 observational ones that give a count, is one of 16 that started in 2024, is one of 40 observational ones, reaches primary completion later than 17 of the 110 other live ones, and was the 311th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:
BeOne Medicines · Sites in Brazil, United States, Australia and 13 more countries
Ages 18+
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 23 more countries
Ages 18+
Hoffmann-La Roche · Sites in Brazil, United States, Argentina and 9 more countries
Ages 18+
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 16 more countries
Ages 18+
Hospital de Clinicas de Porto Alegre · Sites in Brazil
Ages 18–65 · Women only
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 79 · Phase 3 150 · Phase 4 4
First in 1997; this study’s year is marked. 16 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,500 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 250 across the 309 interventional studies, 251 across the 40 observational. Of the 206 that completed or were terminated, 109 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
215 of 351 have an industry lead sponsor. The 10 most frequent:
Federal University of São Paulo is the lead sponsor of 439 studies on the registry; 23 are open to participants now.
Federal University of São Paulo has 6 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
31 of the studies in Breast Neoplasms with a site in Brazil that are under way reach primary completion within a year, 16 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT06839001Phase 3Hospital do CoracaoCRYoablation for Small Tumors As Local Treatment - SIX Trial | 2027-03-01 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT04540692Phase 3Latin American Cooperative Oncology GroupEvaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | 2027-04 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Breast Neoplasms with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer is the most common cancer in women globally, with 2.3 million new cases diagnosed in 2020. Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer is the most prevalent subtype, comprising 69% of all breast cancers in the USA. Within the tumor immune microenvironment, a higher intensity of myeloid cell infiltration and low levels of lymphocyte infiltration have been associated with worse outcomes. Markers in peripheral blood have emerged as predictive biomarkers that can be easily obtained non-invasively and at low cost. Experiments have confirmed the relative components of these tests (such as the immune cells) directly or indirectly participated in tumour occurrence, development, and immune escape, underscoring the potential use of laboratory tests as tumour biomarkers
In breast cancer, increased neutrophil levels and decreased lymphocyte levels in peripheral blood are associated with worse overall survival (OS). In HR+, HER2- metastatic breast cancers, low pretreatment NLR and high pretreatment absolute lymphocyte count (ALC) were related with better progression-free survival (PFS) and OS. The development of predictive models, based on machine learning (ML) algorithms it has been used in prognostication and assist in the diagnosis of different types of cancer.
Although regular laboratory tests have potential to be breast cancer biomarkers, a single test is yet to provide adequate sensitivity or specificity. Artificial intelligence (AI) could help with integrating data from multiple tests to aid diagnosis. Technical improvements such as data storage capacity, computing power, and better algorithms mean that ML can process clinically meaningful information from laboratory test data. Models' generalisability and stability still need to be confirmed, in view of limitations such as the absence of various pathological types, small cohorts, and lack of external validation. Therefore, a competitive model is also essential to achieve more accurate stratification of patients with breast cancer. The purpose of this retrospective multicentre study is to systematically evaluate the ability of laboratory tests to predict breast cancer, and develop a robust and generalisable model to assist in identifying patients with breast cancer.
All the women involved in our study are patients who are diagnosed breast cancer pathologically and treated with surgery or neoadjuvant chemotherapy from January 1st 2013 to December 31st 2018.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presence of hematological disorders;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All the participants involved in our study are women who are diagnosed breast cancer and treated with surgery or neoadjuvant chemotherapy from January 1st 2013 to December 31st 2018.
Procedure: Surgery (Mastectomy or quadrantectomy)
Surgery (mastectomy or quadrantectomy); Neoadjuvant chemotherapy
Also known as: Neoadjuvant chemotherapy
Overall survival
Overall survival
Time frame: From the date of diagnosis to the date of death, assessed up to 120 months
Disease free survival
Disease-free survival
Time frame: From the date of diagnosis to the date of first progression (local recurrence of tumor or distant metastasis), assessed up to 60 months
Plan to share: No
Ran from Aug 2024 to primary completion in Dec 2024, 4 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federal University of São Paulo →